pharma · Weight Loss · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · VKTX
Viking Therapeutics
Viking Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker VKTX. Primary therapeutic focus areas include Weight Loss, Adrenomyeloneuropathy Form (AMN) of X-linked Adrenol
San Diego, USA HQ
2012 Founded
60 Employees
Public company Type
VKTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2012
- Employees
- 60
- Programs
- 6
- Drugs
- 3
- Patents
- 15
VK0214
Phase 1 · small molecule · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
VK0214 for Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) is a Phase 1 program (small_molecule) at Viking Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code VK0214-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Viking Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
- Status
- completed
- Trials
- 1